Company Description
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.
The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair.
It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial.
In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial.
The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University.
Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
| Country | Canada |
| Founded | 2016 |
| IPO Date | Jun 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 129 |
| CEO | Steve Forte |
Contact Details
Address: 7171 Frederick-Banting, Building 2, Suite 270 Montreal, QC H4S 1Z9 Canada | |
| Phone | 857-412-7018 |
| Website | reparerx.com |
Stock Details
| Ticker Symbol | RPTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001808158 |
| CUSIP Number | 760273102 |
| ISIN Number | US7602731025 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steve Forte CPA | President, Chief Financial Officer, Chief Executive Officer and Director |
| Dr. Michael Zinda Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Daniel Durocher Ph.D. | Co-Founder |
| Dr. Frank Sicheri Ph.D. | Co-Founder |
| Dr. Agnel Sfeir Ph.D. | Co-Founder |
| Sandra Alves | Senior Vice President and Chief Accounting Officer |
| Daniel Belanger | Executive Vice President of Human Resources |
| Dr. Joseph P. O'Connell M.D. | Executive Vice President of Clinical Development and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 8, 2025 | 8-K | Current Report |
| Jul 16, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K/A | [Amend] Current report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |